← USPTO Patent Grants

Process for producing a composition of engineered T cells

Grant US12577285B2 Kind: B2 Mar 17, 2026

Assignee

Juno Therapeutics, Inc.

Inventors

Mirna Mujacic, Ayu Rahardjo, Pascal Beauchesne, Kien Khuu-Duong, Ivie Aifuwa, Calvin Chan

Abstract

The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells and/or CD8+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for pooling enriched CD4+ and CD8+ cells, such as at a 1:1 ratio, and then incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

CPC Classifications

A61K 35/17 A61K 2039/5156 A61K 2039/5158 A61K 39/0011 C07K 14/7051 C07K 2319/03 C12N 5/0636 C12N 2510/00 C12N 2500/90 C12N 2501/00 C12N 2501/50 C12N 2501/599 C12N 2501/998

Filing Date

2018-12-07

Application No.

16769971

Claims

53